Best of ASCO - 2014 Annual Meeting

 

Welcome

Chronic Lymphocytic Leukemia (CLL)

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
Acalabrutinib with obinutuzumab (Ob) in treatment-naive (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Three-year follow-up.

Jennifer Ann Woyach

7500

Assessing the potential of immunotherapy in treating chronic lymphocytic leukemia through meta-analysis.

Jihad Aljabban

7531

Atrial fibrillation (AF) in patients with CLL treated with ibrutinib: Assessing prediction models and clinical outcomes.

William Archibald

7522

CAP-100: First-in-class antibody for CCR7+ hematological malignancies.

Carlos Cuesta

e19008

Chronic lymphocytic leukemia: An Indian experience.

Ajay Gogia

e19007

Conceptual model of chronic lymphocytic leukemia.

Helena Chung

e19001

Effect of dose modifications on response to duvelisib in patients with relapsed/refractory (R/R) CLL/SLL in the DUO trial.

Ian Flinn

7523

Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD–) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.

Kirsten Fischer

7502

Expression and prognostic relevance of calcium calmodulin-dependent protein kinase kinase 2 (CaMKK2) in chronic lymphocytic leukemia (CLL).

Shekeab Jauhari

e19002

Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.

Paul M. Barr

7510

Long-term effects of ibrutinib on blood pressure in patients with chronic lymphocytic leukemia (CLL).

Jade Jones

e19009

Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL): Final analysis of the phase 3 COMPLEMENT 1 trial.

Fritz Offner

7528

Minimal residual disease and survival outcomes in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.

Stefano Molica

e19003

Occurrence of other cancers in patients with chronic lymphocytic leukemia and mutations in protection of telomeres 1 (POT1) gene.

Matteo Molica

7529

Outcomes in chronic lymphocytic leukemia (CLL) patients with NOTCH1 signaling pathway mutations.

Daniel R. Helbig

7524

Outcomes of stem cell transplant in patients with Richter transformation.

Yucai Wang

7526

Phase 1/2 trial of cirmtuzumab and ibrutinib: Planned analysis of phase 1 CLL cohorts.

Michael Y. Choi

7527

Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

Kerry Anne Rogers

7530

Second cancer incidence in CLL patients receiving BTK inhibitors.

David Alan Bond

7511

Serum B-cell maturation antigen as a prognostic marker for untreated chronic lymphocytic leukemia.

Camilia M Soof

7525

TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

Tanya Siddiqi

7501

ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

Ian Flinn

TPS7566